BRCA1/2突变家族中健康女性的血清AMH水平是否降低
这项多中心横断面研究于2012年1月至2015年2月纳入255名18-45岁健康女性(124名BRCA1/2突变携带者与131名证实非携带者),比较血清AMH水平。携带者中位AMH为1.90 µg/l,非携带者为1.80 µg/l(P=0.34);校正年龄、当前吸烟和当前激素避孕使用后,携带者AMH无降低(相对变化=0.98,95%CI 0.77-1.22;P=0.76)。
要点
- BRCA1/2突变携带者中位AMH为1.90 µg/l,非携带者为1.80 µg/l(P=0.34)。
- 校正年龄、当前吸烟和当前激素避孕使用后,携带者AMH无降低(相对变化=0.98,95%CI 0.77-1.22;P=0.76)。
- 作者认为现有分析和文献的局限性要求开展前瞻性、良好对照的随访研究并重复测量AMH。
核心结论
- 校正潜在混杂因素后,BRCA1/2突变携带者与证实非携带者相比血清AMH水平未见降低。
研究设计与样本
- 多中心横断面研究,于2012年1月至2015年2月开展,共纳入255名女性。
- 研究需纳入120名BRCA1/2突变携带者和120名证实非携带者,以检出AMH水平差异0.40 µg/l(SD ± 0.12 µg/l,双侧α误差0.05,把握度80%)。
- 研究对象为18-45岁健康女性,因家族性BRCA1/2突变转诊至临床遗传科并申请预测性BRCA1/2检测。
- 通过测量血清AMH水平和填写问卷进行横断面评估。
- 对对数转换后的血清AMH水平进行多变量线性回归分析,校正年龄、当前吸烟和当前激素避孕使用。
主要发现
- 823名潜在合格女性中421名(51.2%)愿意参与,其中166名(39%)不符合纳入标准。
- 255名女性可进行分析,包括124名BRCA1/2突变携带者和131名证实非携带者。
- 携带者中位AMH水平为1.90 µg/l[范围0.11-19.00],非携带者为1.80 µg/l[范围0.11-10.00](P=0.34)。
- 校正线性回归分析显示携带者AMH水平无降低(相对变化=0.98,95%CI 0.77-1.22;P=0.76)。
临床怎么用
- 作者认为当前分析和现有文献的局限性要求开展前瞻性、良好对照的随访研究并重复测量AMH,以确定携带者是否可能面临卵巢储备低下的风险并最终指导照护。
局限性
- 参与者相对年轻。
- 把握度不足以单独分析BRCA1和BRCA2突变携带者。
- AMH水平可能受到激素避孕使用的影响,尽管携带者和非携带者中当前使用者的比例相似,且分析中已校正潜在混杂。
- 作者认为当前分析和现有文献的局限性要求开展前瞻性、良好对照的随访研究并重复测量AMH。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Do BRCA1/2 mutation carriers have a compromised ovarian reserve compared to proven non-carriers, based on serum anti-Müllerian hormone (AMH) levels? SUMMARY ANSWER: BRCA1/2 mutation carriers do not show a lower serum AMH level in comparison to proven non-carriers, after adjustment for potential confounders. WHAT IS KNOWN ALREADY: It has been suggested that the BRCA genes play a role in the process of ovarian reserve depletion, although previous studies have shown inconsistent results regarding the association between serum AMH levels and BRCA mutation status. Hence, it is yet unclear whether BRCA1/2 mutation carriers may indeed be at risk of a reduced reproductive lifespan. STUDY DESIGN, SIZE, DURATION: A multicenter, cross-sectional study was performed between January 2012 and February 2015 in 255 women. We needed to include 120 BRCA1/2 mutation carriers and 120 proven non-carriers to demonstrate a difference in AMH levels of 0.40 µg/l (SD ± 0.12 µg/l, two-sided alpha-error 0.05, power 80%). PARTICIPANTS/MATERIALS, SETTING, METHOD: Healthy women aged 18-45 years who were referred to the Clinical Genetics Department and applied for predictive BRCA1/2 testing because of a familial BRCA1/2 mutation were asked to participate. A cross-sectional assessment was performed by measuring serum AMH levels and filling out a questionnaire. Multivariate linear regression analyses adjusted for age, current smoking and current hormonal contraceptive use were performed on log-transformed serum AMH levels. MAIN RESULTS AND THE ROLE OF CHANCE: Out of 823 potentially eligible women, 421 (51.2%) were willing to participate, and of those, 166 (39%) did not meet our inclusion criteria. Two hundred and fifty-five women were available for analyses; 124 BRCA1/2 mutation carriers and 131 proven non-carriers. The median [range] AMH level in carriers was 1.90 µg/l [0.11-19.00] compared to 1.80 µg/l [0.11-10.00] in non-carriers (P = 0.34). Adjusted linear regression analysis revealed no reduction in AMH level in the carriers (relative change = 0.98 (95%CI, 0.77-1.22); P = 0.76). LIMITATIONS, REASONS FOR CAUTION: Participants were relatively young. Power was insufficient to analyze BRCA1 and BRCA2 mutation carriers separately. AMH levels may have been influenced by the use of hormonal contraceptives, though similar proportions of carriers and non-carriers were current users and adjustments were made to correct for potential confounding in our analysis. WIDER IMPLICATIONS OF THE FINDINGS: Limitations of the current analysis and limitations of the existing literature argue for prospective, well-controlled follow-up studies with recurrent AMH measurements to determine whether carriers might be at risk for low ovarian reserve and to definitively guide care. STUDY FUNDING/COMPETING INTERESTS: This study was partially financially supported by a personal grant for Inge A.P. Derks-Smeets, kindly provided by the Dutch Cancer Society (Grant Number UM 2011-5249). Theodora C. van Tilborg, Inge A.P. Derks-Smeets, Anna M.E. Bos, Jan C. Oosterwijk, Christine E. de Die-Smulders, Lizet E. van der Kolk, Wendy A.G. van Zelst-Stams, Maria E. Velthuizen, Marinus J.C. Eijkemans and Margreet G.E.M. Ausems have nothing to disclose. Ron J. van Golde has received unrestricted research grants from Ferring and Merck Serono, outside the submitted work. Annemieke Hoek received an unrestricted educational grant from Ferring pharmaceutical BV, The Netherlands and a speaker's fee for post graduate education from MSD pharmaceutical company, outside the submitted work. Joop S.E. Laven has received unrestricted research grants from Ferring, Merck Serono, Merck Sharpe & Dome, Organon, and Schering Plough, outside the submitted work. Frank J.M. Broekmans is a member of the external advisory board for Merck Serono (The Netherlands), outside the submitted work. TRIAL REGISTRATION NUMBER: NTR no. 4324.
引用
- van Tilborg TC, Derks-Smeets IA, Bos AM, et al. Serum AMH levels in healthy women from BRCA1/2 mutated families: are they reduced? Hum Reprod. 2016. PMID: 27907901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。